KIZOO

DGAP-News: Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed to Develop Repairing-Based Approaches to Reversing Aging

Retrieved on: 
Thursday, March 17, 2022
Time, Asparaginase, CA, Collagen, Ageing, Technology, Kidney, Death, Mentorship, Health, Patient, Enzyme, Revel, Conference, Therapy, Disease, Cardiovascular disease, Risk, VC, David Evans (Yale professor), Diabetes, Human, Cystic fibrosis, Investment, Stroke, Kidney disease, Research, Cancer, Osteoarthritis, Inflammation, CEO, Yale University, Degenerative disease, Deoxyribonuclease, Longevity, Engineering, Metabolism, Glycogen storage disease, Imiglucerase, Pharmaceutical industry, Seed, KIZOO, Revel Pharmaceuticals, KIZOO, REVEL PHARMACEUTICALS

Led by Kizoo Technology Capital, the Seed round will be used to advance Revel Pharmaceuticals' enzyme therapy pipeline towards the clinic.

Key Points: 
  • Led by Kizoo Technology Capital, the Seed round will be used to advance Revel Pharmaceuticals' enzyme therapy pipeline towards the clinic.
  • San Francisco, CA, U.S., March 17, 2022 - Revel Pharmaceuticals, a longevity therapeutics company developing enzymes to repair damage from aging, announced today that it has raised $8.4M in Seed financing.
  • Revel Pharmaceuticals is reimagining how enzymes can be used as therapeutics by developing repair-based approaches to aging and disease.
  • "Revel is leading innovation in repair-based approaches to aging", says Patrick Burgermeister, Partner at Kizoo Technology Capital and board member of Revel Pharmaceuticals.

Elastrin Therapeutics Announces Newly Formed Scientific Advisory Board

Retrieved on: 
Monday, January 17, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Linda, Clemson University, EDTA, Green College, Hotel des Indes (The Hague), VP, MAA, Industry, Therapy, Hospital, Grünenthal, LLC, Yuri, Health authority, NDA, Investment, Technology, Ageing, Conference, Pangborn Sensory Science Symposium, CTAS, Degenerative disease, Corporation, MBA, Cardiovascular disease, Health, Associate, Doctor of Philosophy, NICE, VC, Head, Elastin, United States Air Force Scientific Advisory Board, Patient, CMO, Chronic kidney disease, Reader, Mentorship, University, III, Board, Harvard Medical School, Winnipeg Regional Health Authority, Seminal vesicles, CEO, University of California, San Diego, MD, Calcification, Pharmaceutical industry, Management, Research, Brigham, Pediatrics, Medicine, Elastrin Therapeutics Inc., KIZOO, ELASTRIN THERAPEUTICS INC., KIZOO

Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board.

Key Points: 
  • Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the formation of its Scientific Advisory Board.
  • We are fortunate to work with such an amazing group of medical scientists, cardiovascular experts and pharma executives on our Scientific Advisory Board, said Dr. Matthias Breugelmans, CEO of Elastrin Therapeutics.
  • Elastrin is a prime example of what Kizoo is looking for in its investments: Not delaying an age-related disease but reversing it, said Patrick Burgermeister, Partner at Kizoo Technology Capital and member of Elastrin Therapeutics Board of Directors.
  • Elastrin Therapeutics Scientific Advisory Board is comprised of:
    Prof. Charles O'Neill, MD: Dr. ONeill has had an active basic and clinical research program in vascular calcification for the past 20 years and has published over 45 articles on this subject.

DGAP-News: Kizoo Portfolio Company Underdog Closes $10M Financing Round

Retrieved on: 
Thursday, September 23, 2021
Mentorship, Innovation, Plaque, Stroke, Mountain View, Ageing, Investment, Atherosclerosis, Conference, Health, Death, Degenerative disease, Infarction, Cardiovascular disease, VCS, Research, United Kingdom, Dark Seed II, Pharmaceutical industry, KIZOO, Underdog, KIZOO, UNDERDOG

Mountain View, CA, U.S., September 23, 2021 - Underdog Pharmaceuticals, a key investment of Michael Greve's rejuvenation biotech VC Kizoo, has closed a $10 million round of capital.

Key Points: 
  • Mountain View, CA, U.S., September 23, 2021 - Underdog Pharmaceuticals, a key investment of Michael Greve's rejuvenation biotech VC Kizoo, has closed a $10 million round of capital.
  • Kizoo led the company's Series Seed II round, which saw participation from both existing and new investors.
  • Underdog was recently awarded the Innovation Passport under the United Kingdom's Innovative Licensing and Access Pathway (ILAP).
  • Kizoo provides mentoring, seed and follow-on financing with a focus on rejuvenation biotech.

Elastrin Therapeutics Strengthens its Leadership Team by Appointing Pedro M. Quintana Diez, MD as Chief Medical Officer

Retrieved on: 
Wednesday, April 28, 2021
Biotechnology, Medical devices, Health, Technology, Software, AbbVie, Companies, Illinois, Health care, Elastrin Therapeutics Inc., KIZOO, ELASTRIN THERAPEUTICS INC., KIZOO

b"Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the appointment of Pedro M. Quintana Diez, MD as Chief Medical Officer.

Key Points: 
  • b"Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again, announced the appointment of Pedro M. Quintana Diez, MD as Chief Medical Officer.
  • \xe2\x80\x9cHis deep knowledge of cardiovascular research and medicine from both an industry and academic perspective is a strong addition to Elastrin preparing for clinical trials.
  • Prior to joining Elastrin Therapeutics, Pedro served as Chief Medical Officer of Sensory Sciences LLC and held VP and leadership positions at Grunenthal, Abbvie and ParinGenix, where he developed clinical strategies and plans across all phases of clinical development, through life-cycle management key decisions.
  • Our team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries.

Kizoo Provides Seed Funding for Elastrin Therapeutics to Develop Groundbreaking New Technology Capable of Reversing Tissue and Organ Calcification

Retrieved on: 
Thursday, March 4, 2021
Biotechnology, Pharmaceutical, Health, Cardiology, Biomineralization, Calcification, Calcium, Histopathology, Elastrin Therapeutics Inc., KIZOO

Elastrin is a biotechnology startup leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again.

Key Points: 
  • Elastrin is a biotechnology startup leveraging a platform technology to develop therapeutics that render calcified tissue and organs supple again.
  • It is the latest addition to the growing portfolio of Kizoo Technology Capital, a rejuvenation biotech investor focused on reversing age-related damage on a cellular and molecular level.
  • Elastrins lead asset is a nanoparticle conjugated with a novel monoclonal antibody for the treatment of heart valve and vascular calcification.
  • The Elastrin team has developed a platform that can restore vascular health by removing pathological calcification specifically from sites where elastin has been degraded.

DGAP-News: Harvard spin-off CELLVIE closes $5M seed round in pursuit of a new treatment modality: therapeutic mitochondria transfer

Retrieved on: 
Monday, January 25, 2021
Mitochondria, Cellular respiration, Mitochondrion, cellvie Inc., KIZOO

Harvard spin-off CELLVIE closes $5M seed round in pursuit of a new treatment modality: therapeutic mitochondria transfer

Key Points: 
  • Harvard spin-off CELLVIE closes $5M seed round in pursuit of a new treatment modality: therapeutic mitochondria transfer
    The issuer is solely responsible for the content of this announcement.
  • "That is why we turned to introducing healthy, viable mitochondria into cells where these organelles are impaired.
  • The potential of Therapeutic Mitochondria Transfer was recently demonstrated in a clinical investigation at Boston Children's Hospital.
  • Founded in the US and headquartered close to Zrich, Switzerland, cellvie is developing medicines from cells, leveraging the therapeutic potential of mitochondria.